HER2 Positive Metastatic Breast Cancer Clinical Trial
Official title:
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
This study plans to explore the efficacy and safety of chemotherapy combined with inetetamab and PD-1 inhibitors in HER2 positive advanced breast cancer who failed to receive trastuzumab and TKIs, and explore the dominant population of dual antibody combination to further guide the precise and individualized treatment of advanced HER2 positive breast cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04829604 -
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
|
Phase 2 | |
| Active, not recruiting |
NCT03691051 -
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03080805 -
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
|
Phase 3 | |
| Active, not recruiting |
NCT02422199 -
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
|
Phase 1/Phase 2 | |
| Terminated |
NCT01495884 -
The Myocet/Lapatinib Study. ICORG 10-03, V5
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02973737 -
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT04398108 -
A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
|
Phase 1 |